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For reprints contact: reprints@medknow.com of plasma cells which constituted approximately 15% of all nucleated cells, and serum protein electrophoresis showed a monoclonal M spike in the gamma globulin region. Hence, a diagnosis of primary systemic amyloidosis caused by multiple myeloma was made, and the patient was started on treatment with thalidomide and bortezomib in consultation with the oncologist. plasma cell dyscrasia or multiple myeloma. It is composed of immunoglobulin light chains. Multiple myeloma is a bone marrow plasma cell dyscrasia diagnosed when there are more than 10% plasma cells in the bone marrow or a plasmocytoma and at least one of the following findings: (1) monoclonal serum protein; (2) monoclonal urine protein; and (3) lytic bone lesions. [1] The prevalence of amyloidosis associated with multiple myeloma varies from 13% to 26%. [2] Cutaneous involvement, seen in 40% of the cases, [3] depends on the site of amyloid deposited. 
Primary systemic amyloidosis (AL amyloidosis) is usually associated with
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